Released Jul 25, 2019, after the close
10-Q filed Aug 8, 2019, 39 days after period end · 0001171843-19-005344
Q2 2019 · 10-Q
Revenue$29.58M$29.58M −6.1% vs Q2 2018+4.9% vs Q1 2019
Net Income-$247.00K-$247.00K N/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$0.01-$0.01 N/M vs Q2 2018N/M vs Q1 2019
Gross Profit$15,955,000+3.9%
Operating Income$228,000N/M
Operating Cash Flowderived$657,000−48.6%
Free Cash Flowderived$377,000−66.8%
Margins · derived
Gross margin53.9%+5.2 pt vs Q2 2018
Operating margin0.8%+2.0 pt vs Q2 2018
Net margin-0.8%+3.8 pt vs Q2 2018
What the release said
The release
Same quarter
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Revenue | $29.58M | $31.52M | $18.96M | $26.14M |
| Net Income | -$247.00K | -$1.46M | -$381.00K | -$713.00K |
| EPS Diluted | -$0.01 | -$0.04 | -$0.01 | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR